This study focuses on individuals living with episodic migraine, a condition characterized by recurring headaches that occur at certain intervals. The purpose of the study is to evaluate the potential benefit and safety of a medication called omalizumab, which is also known by the brand name Xolair. This medicine is administered as a subcutaneous injection, which means it is delivered through a needle into the fatty layer of tissue just under the skin.

Participants will receive the medication to see how it affects the number of days they experience a migraine each month. During the study, the frequency, intensity, and duration of the headaches will be monitored. The researchers will also observe any adverse events, which are any side effects or unexpected health changes that occur during the treatment period.